These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2431716)

  • 1. Mechanisms of natural cell-mediated resistance in human solid tumors.
    Allavena P; Merendino A; Di Bello M; Pirelli A; Rossini S; Mantovani A
    Biochim Biophys Acta; 1986 Dec; 865(3):281-8. PubMed ID: 2431716
    [No Abstract]   [Full Text] [Related]  

  • 2. Impaired cell-mediated immunity in hemophilia. II. Persistence of subclinical immunodeficiency and enhancement of natural killer activity by lymphokines.
    Lederman MM; Ratnoff OD; Schacter B; Shoger T
    J Lab Clin Med; 1985 Aug; 106(2):197-204. PubMed ID: 2410523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian-tumor-infiltrating lymphocytes: phenotype and antitumor activity.
    Lotzová E
    Nat Immun Cell Growth Regul; 1988; 7(4):226-9. PubMed ID: 3266295
    [No Abstract]   [Full Text] [Related]  

  • 4. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
    Grimm EA; Mazumder A; Zhang HZ; Rosenberg SA
    J Exp Med; 1982 Jun; 155(6):1823-41. PubMed ID: 6176669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Biological immunomodulators in the treatment of cancer].
    Bello C; Richard C; Hermosa V; Iriondo A; Muruzábal MJ; Pérez Encinas M; Zubizarreta A
    Sangre (Barc); 1988 Apr; 33(2):132-43. PubMed ID: 2456623
    [No Abstract]   [Full Text] [Related]  

  • 6. Infiltration of interleukin-2-inducible killer cells in ascitic fluid and pleural effusions of advanced cancer patients.
    Blanchard DK; Kavanagh JJ; Sinkovics JG; Cavanagh D; Hewitt SM; Djeu JY
    Cancer Res; 1988 Nov; 48(22):6321-7. PubMed ID: 2972357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-2 augments natural killer cell activity.
    Henney CS; Kuribayashi K; Kern DE; Gillis S
    Nature; 1981 May; 291(5813):335-8. PubMed ID: 6164929
    [No Abstract]   [Full Text] [Related]  

  • 8. Natural killer cells.
    Herberman RB
    Prog Clin Biol Res; 1989; 288():161-7. PubMed ID: 2470107
    [No Abstract]   [Full Text] [Related]  

  • 9. Lymphokine-activated killer activity of tumor-associated and peripheral blood lymphocytes isolated from patients with ascites ovarian tumors.
    Allavena P; Zanaboni F; Rossini S; Merendino A; Bonazzi C; Vassena L; Mangioni C; Mantovani A
    J Natl Cancer Inst; 1986 Oct; 77(4):863-8. PubMed ID: 3489856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunosuppressive effects of peritoneal fluids from ovarian cancer patients.
    Onsrud M
    Gynecol Oncol; 1986 Mar; 23(3):316-22. PubMed ID: 3957117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signal requirements for lymphocyte activation: role of a T-cell growth factor produced by guinea pig peritoneal exudate lymphocytes.
    Weinblatt AC; Oppenheim JJ; Rosenstreich DL
    Cell Immunol; 1982 Apr; 68(2):332-42. PubMed ID: 6980058
    [No Abstract]   [Full Text] [Related]  

  • 12. Lymphocyte stimulation by phytohemagglutinin and tumor cells of malignant effusions.
    Robinson E; Sher S; Mekori T
    Cancer Res; 1974 Jul; 34(7):1548-51. PubMed ID: 4275697
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of interferon and lymphokines on lymphocytes.
    Gifford GE; Tobey M
    Tex Rep Biol Med; 1977; 35():375-80. PubMed ID: 358461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-infiltrating lymphocytes from human solid tumors: antigen-specific killer T lymphocytes of activated natural killer lymphocytes.
    Whiteside TL; Heo DS; Takagi S; Herberman RB
    Immunol Ser; 1989; 48():139-57. PubMed ID: 2488318
    [No Abstract]   [Full Text] [Related]  

  • 15. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
    Itoh K; Tilden AB; Balch CM
    J Immunol; 1986 May; 136(10):3910-5. PubMed ID: 3084648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphocyte activation by recombinant interleukin-2 in ovarian cancer patients.
    Boyer PJ; Berek JS; Zighelboim J
    Obstet Gynecol; 1989 May; 73(5 Pt 1):793-7. PubMed ID: 2784847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunologic control of ovarian cancer.
    Zighelboim J; Nio Y; Berek JS; Bonavida B
    Nat Immun Cell Growth Regul; 1988; 7(4):216-25. PubMed ID: 3070371
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of biological response modifiers on effector cells with cytotoxic activity against tumors.
    Herberman RB
    Semin Oncol; 1986 Jun; 13(2):195-9. PubMed ID: 2424088
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunotherapy of solid tumor by intratumoral infusion of lymphokine-activated killer cells.
    Yamaki T; Ibayashi Y; Nakamura T; Shijubo N; Daibo M; Kawahara T; Hashi K
    Jpn J Cancer Res; 1988 Aug; 79(8):903-8. PubMed ID: 3141326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mediators of immunity: lymphokines and monokines.
    Rocklin RE; Bendtzen K; Greineder D
    Adv Immunol; 1980; 29():55-136. PubMed ID: 6158261
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.